TrialFuture oncology (London, England)2025

POLARIS: encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.

Alexander M Menzies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.